Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02520011
Title Alvocidib Biomarker-driven Phase 2 AML Study
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Tolero Pharmaceuticals, Inc.
Indications
Therapies
Age Groups: adult
Covered Countries USA | GBR | ESP | CAN


No variant requirements are available.